On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review

References

• Alasil T, Keane PA, Updike JF et al. Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema. Ophthalmology 2010; 117: 2379–2386.
   PubMed Web of Science ®Google Scholar
• Keenan TDL, Johnston RL, Donachie PHJ et al. United Kingdom national ophthalmology database study: Diabetic retinopathy; report 1: Prevalence of centre‐involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services. Eye 2013; 27: 1397–1404.
   Web of Science ®Google Scholar
• Ferris FL, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984; 28 Suppl: 452–461.
   Google Scholar
• Bhagat N, Grigorian RA, Tutela A et al. Diabetic macular edema: Pathogenesis and treatment. Surv Ophthalmol 2009; 54: 1–32.
   PubMed Web of Science ®Google Scholar
• Chen E, Looman M, Laouri M et al. Burden of illness of diabetic macular edema: Literature review. Curr Med Res Opin 2010; 26: 1587–1597.
   PubMed Web of Science ®Google Scholar
• Otani T, Yamaguchi Y, Kishi S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina 2010; 30: 774–780.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Wong TY, Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema. Am J Ophthalmol 2014; 157: 505–513.
   PubMed Web of Science ®Google Scholar
• Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. Ophthalmologica 2007; 221: 95–102.
   PubMed Web of Science ®Google Scholar
• O'doherty M, Dooley I, Hickey‐dwyer M. Interventions for diabetic macular oedema: A systematic review of the literature. Br J Ophthalmol 2008; 92: 1581–1590.
   Web of Science ®Google Scholar
• Meyer CH. Current treatment approaches in diabetic macular edema. Ophthalmologica 2007; 221: 118–131.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep 2012; 12: 364–375.
   PubMed Web of Science ®Google Scholar
• Bandello F, Casalino G, Loewenstein A et al. Pharmacological approach to diabetic macular edema. Ophthal Res 2014; 51: 88–95.
   PubMed Web of Science ®Google Scholar
• Okada K, Yamamoto S, Mizunoya S et al. Correlation of retinal sensitivity measured with fundus‐related microperimetry to visual acuity and retinal thickness in eyes with diabetic macular edema. Eye 2006; 20: 805–809.
   PubMed Web of Science ®Google Scholar
• Vujosevic S, Midena E, Pilotto E et al. Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci 2006; 47: 3044–3051.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Danis R, Glassman A et al. Diurnal variation in retinal thickening measurement by optical coherence tomography in center‐involved diabetic macular edema. Arch Ophthalmol 2006; 124: 1701–1707.
   PubMedGoogle Scholar
• Hatef E, Khwaja A, Rentiya Z et al. Comparison of time domain and spectral domain optical coherence tomography in measurement of macular thickness in macular edema secondary to diabetic retinopathy and retinal vein occlusion. J Ophthalmol 2012; 2012: 354783.
   PubMed Web of Science ®Google Scholar
• Dmuchowska DA, Krasnicki P, Mariak Z. Can optical coherence tomography replace fluorescein angiography in detection of ischemic diabetic maculopathy? Graefes Arch Clin Exp Ophthalmol 2014; 252: 731–738.
   Web of Science ®Google Scholar
• Larsson J, Zhu MD, Sutter F et al. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005; 139: 802–806.
   Web of Science ®Google Scholar
• Chan A, Duker JS, Ko TH et al. Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 2006; 124: 193–198.
   PubMedGoogle Scholar
• Wolf‐schnurrbusch UE, Ceklic L, Brinkmann CK et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Visual Sci 2009; 50: 3432–3437.
   PubMed Web of Science ®Google Scholar
• Nunes S, Pereira I, Santos A et al. Central retinal thickness measured with HD‐OCT shows a weak correlation with visual acuity in eyes with CSMA. Br J Ophthalmol 2010; 94: 1201–1204.
   Web of Science ®Google Scholar
• Sull AC, Vuong LN, Price LL et al. Comparison of spectral/Fourier domain optical coherence tomography instruments for assessment of normal macular thickness. Retina 2010; 30: 235–245.
   PubMed Web of Science ®Google Scholar
• Grover S, Murthy RK, Brar VS et al. Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography. Invest Ophthalmol Visual Sci 2010; 51: 2644–2647.
   PubMed Web of Science ®Google Scholar
• Forte R, Cannamo GL, Finelli ML et al. Comparison of time domain Stratus OCT and spectral domain SLO / OCT for assessment of macular thickness and volume. Eye 2009; 23: 2071–2078.
   PubMed Web of Science ®Google Scholar
• Modjtahedi S, Chiou C, Modjtahedi B et al. Comparison of macular thickness measurement and segmentation error rate between Stratus and Fourier‐domain optical coherence tomography. Ophthal Surg Laser Imaging 2010; 41: 301–310.
   Google Scholar
• Pelosini L, Hull CC, Boyce JF et al. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci 2011; 52: 2741–2748.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Lee SH, Chung H et al. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2012; 250: 61–70.
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Sepah YJ, Symons RCA et al. Spectral‐ and time‐domain optical coherence tomography measurements of macular thickness in normal eyes and eyes with diabetic macular edema. Eye 2012; 26: 454–462.
   PubMed Web of Science ®Google Scholar
• Beck RW, Moke PS, Turpin AH et al. A computerized method of visual acuity testing: Adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 2003; 135: 194–205.
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985; 103: 1796–1806.
   PubMed Web of Science ®Google Scholar
• Yuksel E, Ozdek S, Yuksel N et al. Intravitreal bevacizumab treatment for refractory diabetic macular edema. Int Ophthalmol 2013; 33: 659–663.
   Web of Science ®Google Scholar
• Sivaprasad S, Crosby‐nwaobi R et al. Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT report 5). Br J Ophthalmol 2013; 97: 1177–1180.
   Web of Science ®Google Scholar
• Solaiman KAM, Diab MM, Dabour SA. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema. Retina 2013; 33: 1623–1629.
   Web of Science ®Google Scholar
• Soheilian M, Garfami KH, Ramezani A et al. Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 2012; 32: 314–321.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Obudi A et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116: 1142–1150.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Yaseri M et al. Initial macular thickness and response to treatment in diabetic macular edema. Retina 2011; 31: 1564–1573.
   Web of Science ®Google Scholar
• Tareen I, Rahman A, Mahar PS et al. Primary effects of intravitreal bevacizumab in patients with diabetic macular edema. Pakistan J Med Sci 2013; 29: 1018–1022.
   Web of Science ®Google Scholar
• Tas M, Oner V, Alakus MF et al. Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema. Int Ophthalmol 2013; 33: 375–380.
   Web of Science ®Google Scholar
• Koytak A, Altinisik M, Sari ES et al. Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema. Eye 2013; 27: 716–721.
   PubMed Web of Science ®Google Scholar
• Costagliola C, Daniele A, Dell'omo R et al. Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection. Exp Eye Res 2013; 110: 50–54.
   PubMed Web of Science ®Google Scholar
• Shoeibi N, Ahmadieh H, Entezari M et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: Long‐term results of a clinical trial. J Ophthal Vis Res 2013; 8: 99–106.
   Google Scholar
• Arevalo JF, Fromow‐guerra J, Quiroz‐mercado H et al. Primary intravitreal bevaciumab (Avastin) for diabetic macular edema ‐ results from the Pan‐American collaborative retina study group at 6‐month follow‐up. Ophthalmology 2007; 114: 743–750.
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Lasave AF, Wu L et al. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema results of the Pan‐American Collaborative Retina Study group at 24 months. Retina 2013; 33: 403–413.
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Sanchez JG, Fromow‐guerra J et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: Results from the Pan‐American collaborative retina study group (PACORES) at 12‐month follow‐up. Graefes Arch Clin Exp Ophthalmol 2009; 247: 735–743.
   PubMed Web of Science ®Google Scholar
• Azad R, Sain S, Sharma YR et al. Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study. Oman J Ophthalmol 2012; 5: 166–70.
   Google Scholar
• Rajendram R, Fraser‐bell S, Kaines A et al. A 2‐year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema 24‐month data: Report 3. Arch Ophthalmol 2012; 130: 972–979.
   PubMed Web of Science ®Google Scholar
• Erol N, Gursoy H, Kimyo S et al. Vision, retinal thickness, and foveal avascular zone size after intravitreal bevacizumab for diabetic macular edema. Adv Therap 2012; 29: 359–369.
   Web of Science ®Google Scholar
• Lim JW, Lee HK, Shin MC. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: A randomized clinical trial. Ophthalmologica 2012; 227: 100–106.
   PubMed Web of Science ®Google Scholar
• Isaac DL, Abud MB, Frantz KA et al. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: A randomized double‐blind study. Acta Ophthalmol 2012; 90: 56–60.
   Web of Science ®Google Scholar
• Kook PE, Maier M, Schuster T et al. Nine‐month results of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular oedema: A retrospective analysis. Acta Ophthalmol 2011; 89: 769–773.
   Web of Science ®Google Scholar
• Song JH, Lee JJ, Lee SJ. Comparison of the short‐term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema. Korean J Ophthalmol 2011; 25: 156–160.
   Google Scholar
• Wang Y‐S, Li X, Wang H‐Y et al. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. Chin Med J 2011; 124: 352–358.
   Web of Science ®Google Scholar
• Marey HM, Ellakwa AF. Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema. Clin Ophthalmol 2011; 5: 1011–1016.
   Google Scholar
• Kim M, Lee P, Kim Y, Yu SY, Kwak HW. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Ophthalmologica 2011; 226: 138–144.
   PubMed Web of Science ®Google Scholar
• Gulkilik G, Taskapili M, Kocabora S et al. Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy. Int Ophthalmol 2010; 30: 697–702.
   Google Scholar
• Michaelides M, Fraser‐bell S, Hamilton R et al. Macular perfusion determined by fundus fluorescein angiography at the 4‐month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT STUDY): Report 1. Retina 2010; 30: 781–786.
   PubMed Web of Science ®Google Scholar
• Kreutzer TC, Al saeidi R, Kook D et al. Comparison of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular edema. Ophthalmologica 2010; 224: 258–264.
   PubMed Web of Science ®Google Scholar
• Roh MI, Kim JH, Kwon OW. Features of optical coherence tomography are predictive of visual outcomes after intravitreal bevacizumab injection for diabetic macular edema. Ophthalmologica 2010; 224: 374–380.
   PubMed Web of Science ®Google Scholar
• Wu P, Lai C, Chen C et al. Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment. J Ocular Pharmacol Therap 2012; 28: 59–64.
   Web of Science ®Google Scholar
• Welch DE, Elmariah H, Peden MC et al. Short‐term response of macular oedema to intravitreal bevacizumab. Br J Ophthalmol 2009; 93: 1033–1036.
   Web of Science ®Google Scholar
• Bonin‐filho M, Costa RA, Calucci D et al. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: One‐year results of a pilot study. Am J Ophthalmol 2009; 147: 1022–1030.
   Web of Science ®Google Scholar
• Seo JW, Park IW. Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol 2009; 23: 17–22.
   Google Scholar
• Paccola L, Costa RA, Folgosa MS et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008; 92: 76–80.
   PubMed Web of Science ®Google Scholar
• Nepomuceno AB, Takaki E, Paes de almeida FP et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol 2013; 156: 502–510.
   Web of Science ®Google Scholar
• Shimura M, Nakazawa T, Yasuda K et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008; 145: 854–861.
   PubMed Web of Science ®Google Scholar
• Kernt M, Cserhati S, Seidensticker F et al. Improvement of diabetic retinopathy with intravitreal ranibizumab. Diabetes Res Clin Pract 2013; 100: E11–E13.
   Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789–801.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA et al. Two‐year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ‐2) study. Ophthalmology 2010; 117: 2146–2151.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt‐erfurth U et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615–625.
   PubMed Web of Science ®Google Scholar
• Kotsolis AI, Tsianta E, Niskopoulou M et al. Ranibizumab for diabetic macular edema difficult to treat with focal/grid laser. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1553–1557.
   Web of Science ®Google Scholar
• Reznicek L, Cserhati S, Seidensticker F et al. Functional and morphological changes in diabetic macular edema over the course of anti‐vascular endothelial growth factor treatment. Acta Ophthalmol 2013; 91: e529–e536.
   PubMed Web of Science ®Google Scholar
• Querques G, Bux AV, Martinelli D et al. Short‐term fluctuation of diabetic macular edema after intravitreal ranibizumab injection. Retina 2009; 29: 1274–1281.
   PubMed Web of Science ®Google Scholar
• Massin P, Audren F, Haouchine B et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema ‐ preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218–224.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Islam FMA, Larsson J et al. Triamcinolone‐induced cataract in eyes with diabetic macular oedema: 3‐year prospective data from a randomized clinical trial. Clin Experiment Ophthalmol 2010; 38, 605–612.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FK, Simpson JM et al. Intravitreal triamcinolone for refractory diabetic macular edema ‐ two‐year results of a double‐masked, placebo‐controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533–1538.
   PubMed Web of Science ®Google Scholar
• Lam DSC, Chan CKM, Mohamed S et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema ‐ six‐month outcomes. Ophthalmology 2007; 114: 2162–2167.
   PubMed Web of Science ®Google Scholar
• Lam DSC, Chan CKM, Mohamed S et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007; 91: 199–203.
   PubMed Web of Science ®Google Scholar
• Lam DSC, Chan CKM, Tang EWH et al. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: Six‐month prospective longitudinal pilot study. Clin Experiment Ophthalmol 2004; 32: 569–572.
   PubMed Web of Science ®Google Scholar
• Audren F, Erginay A, Haouchine B et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6‐month results of a prospective controlled trial. Acta Ophthalmol Scand 2006; 84: 624–630.
   PubMedGoogle Scholar
• Audren F, Lecleire‐collet A, Erginay A et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: Phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006; 142: 794–799.
   PubMed Web of Science ®Google Scholar
• Gibran SK, Cullinane A, Jungkim S et al. Intravitreal triamcinolone for diffuse diabetic macular oedema. Eye 2006; 20: 720–724.
   PubMed Web of Science ®Google Scholar
• Lavinsky D, Cardillo JA, Melo LAS et al. Randomized clinical trial evaluating mETDRS versus normal or high‐density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 2011; 52: 4314–4323.
   PubMed Web of Science ®Google Scholar
• Kumar V, Ghosh B, Mehta DK et al. Functional outcome of subthreshold versus threshold diode laser photocoagulation in diabetic macular oedema. Eye 2010; 24: 1459–1465.
   PubMed Web of Science ®Google Scholar
• Figueira J, Khan J, Nunes S et al. Prospective randomised controlled trial comparing sub‐threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 2009; 93: 1341–1344.
   PubMed Web of Science ®Google Scholar
• Sobaci G, Ozge G, Erdurman C et al. Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema. Ophthalmologica 2012; 227: 95–99.
   Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR et al. Relationship between optical coherence tomography‐measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114: 525–536.
   PubMed Web of Science ®Google Scholar
• Jardeleza MSR, Miller JW. Review of anti‐VEGF therapy in proliferative diabetic retinopathy. Sem Ophthalmol 2009; 24: 87–92.
   PubMed Web of Science ®Google Scholar
• Ford JA, Lois N, Royle P et al. Current treatments in diabetic macular oedema: systematic review and meta‐analysis. BMJ Open 2013; 3: e002269.
   Web of Science ®Google Scholar
• Korobelnik J‐F, Do DV, Schmidt‐erfurth U et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121: 2247–2254.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New Engl J Med 2015; 372: 1193–1203.
   PubMed Web of Science ®Google Scholar